| Document |
Document Title |
|
WO/2016/198613A1 |
The present invention relates to N-(thio)acylimino compoundsof formula (I) wherein the variables are as defined in the claims and the description, and the stereoisomers, tautomers and salts thereof. The invention further relates to agric...
|
|
WO/2016/197959A1 |
The present invention relates to the compound of formula (I) used for detecting dihydroorotate dehydrogenase. In formula (I), A is pigment group, L is link arm, R is specific binding ligand for dihydroorotate dehydrogenase. The compound ...
|
|
WO/2016/193111A1 |
A compound of Formula (I), or a salt thereof, compositions comprising the compound, processes for its preparation and its use in therapy, for example in the treatment of parasitic diseases such as Chagas disease, Human African Trypanosom...
|
|
WO/2016/194024A1 |
The present invention aims to provide an agent for the treatment of giardiasis. Provided is an antigiardial agent that includes a compound represented by general formula (1) and/or a salt thereof. The antigiardial agent is preferably for...
|
|
WO/2016/197049A1 |
Antimicrobial peptides, compositions and methods are described that are useful for treating infectious diseases, including those caused by drug resistant Gram-negative bacteria (e.g., Pseudomonas and Acinetobacter) and parasite-caused di...
|
|
WO/2016/184784A1 |
The invention relate to isolated peptides including binding domain of the Plasmodium Falciparum proteins (CBP1 and CBP2) to the chemokine CX3CL1 which has the property to inhibit the cytoadherence of infected red blood cells (iRBC) to en...
|
|
WO/2016/185135A1 |
The present invention relates to methods and compositions for preventing, treating and diagnosing infection by trypanosomes. The invention also relates to the use of excreted/secreted antigens (exoantigens, secretome) and specifically to...
|
|
WO/2016/182032A1 |
Provided is a prophylactic and/or therapeutic agent for fungal eye infection or acanthamoeba eye infection, said prophylactic and/or therapeutic agent comprising an azole antifungal agent as an active ingredient, characterized in that th...
|
|
WO/2016/181187A1 |
The invention relates to a composition for treatment against gregarine infestation in shrimp, characterised in that it comprises an active compound selected from lasalocid, salinomycin, narasin, maduramicin, semduramicin, 3-nitrophenyl a...
|
|
WO/2016/177884A1 |
Medetomidine or a salt thereof for use in controlling parasitic crustaceans, such as sea lice, on fish, e.g. salmon. A method of improving water flow into and out of a cage or net for fish farming, by providing said cage or net with a su...
|
|
WO/2016/172762A1 |
An immunogenic composition comprises one or a plurality of isolated proteins comprising respective amino acid sequences set forth in SEQ ID NOS:1-3, or a fragment or variant thereof; one or a plurality of isolated nucleic acids encoding ...
|
|
WO/2016/176450A1 |
Embodiments of tambjamines and B-ring functionalized prodiginines are disclosed. Methods of synthesizing and using the disclosed compounds are also disclosed. Some embodiments of the disclosed compounds have antimalarial activity. Certai...
|
|
WO/2016/175264A1 |
Provided are: a compound that is a novel 2,4,6-substituted triazine derivative and a 2,4,6-substituted pyrimidine derivative, and is expressed by formula (I) (in the formula, A is CH or N, Z is an optionally substituted alkoxy group, an ...
|
|
WO/2016/170280A1 |
The present invention relates to a composition comprising a therapeutically effective amount of Bacteroides thetaiotaomicron or an extract thereof for use in the prevention or treatment of an infection in a subject who is immunodepressed...
|
|
WO/2016/169906A1 |
The present invention relates to a compound of Formula (I) having pharmacological activity, processes for its preparation, pharmaceutical compositions and their use in the treatment of certain parasitic certain parasitic protozoal infect...
|
|
WO/2016/172261A1 |
The disclosure provides for methods and compositions for treating a T. cruzi infection and/or Chagas Disease.
|
|
WO/2016/169908A1 |
The present invention relates to a compound of Formula (I) having pharmacological activity, processes for its preparation, pharmaceutical compositions and their use in the treatment of certain parasitic certain parasitic protozoal infect...
|
|
WO/2016/168911A1 |
The present invention is directed to purine nucleoside analogs of the general formula (I) or salts and pharmaceutical compositions comprising such compounds and salts, which are useful as anti-protozoan agents. The invention is also dire...
|
|
WO/2016/168536A1 |
The present invention provides cell egress and invasion inhibitors and their use as antiparasitical agents.
|
|
WO/2016/164814A1 |
This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therape...
|
|
WO/2016/162640A1 |
The invention relates to composition 1 in the form of a gel. Said composition is suitable for topical application and is made up of: between 1 and 40% NaCl, between 0.5 and 10% hydroxyethyl cellulose, or between 20 and 50% sodium lauryl ...
|
|
WO/2016/164412A1 |
Embodiments of small molecule inhibitors of hypoxia inducible factor 1 (HIF-1) and pharmaceutical compositions thereof are disclosed. The disclosed compounds suppress HIF-1 activity by inhibiting the interaction between the HIF- 1 α sub...
|
|
WO/2016/164487A1 |
This invention relates to extended release injectable formulations for combating parasites in animals, comprising at least one isoxazoline active agent, a pharmaceutically acceptable polymer, and a solvent. This invention also provides f...
|
|
WO/2016/160429A1 |
Certain embodiments are directed to an immunogenic composition comprising an immunogenic glycoconjugate comprising a glycan having the chemical formula of galactopyranose (Galp)-α(1,2)-R, Galp-α(1,3)-R, Galp-α(1,4)-R, or Galp-α( 1,6)...
|
|
WO/2016/161369A1 |
The present invention relates to a veterinary composition comprising an effective amount of at least one cyclic depsipeptide and at least one macrocyclic lactone; and a pharmaceutically acceptable carrier, for the treatment or prophylaxi...
|
|
WO/2016/155118A1 |
Disclosed is a medicine for treating animal eperythrozoonosis. The medicine comprises the following effective components in parts by weight: 0.25-2.5 parts of artesunate, 0.1-1 part of arteether and 0.25-2.5 parts of artemether.
|
|
WO/2016/151521A1 |
The present invention is related to a use of triazolopyrimidine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to triazolopyrimidine derivatives useful fo...
|
|
WO/2016/152767A1 |
The present invention provides an oligodeoxynucleotide containing humanized K-type CpG oligodeoxynucleotide and polydeoxyadenylic acid, wherein the polydeoxyadenylic acid is located on the 3' side of the humanized K-type CpG oligodeoxynu...
|
|
WO/2016/153078A1 |
This is a combination therapy involving use of suramin and its derivatives with Arginase inhibitors to give multifaceted interruption of cancer progression. It also brings immune system restoration and boost to improve disease management...
|
|
WO/2016/149460A1 |
The present disclosure is directed to an immunogenic composition and method for preventing or treating a filarial disease including: at least one or at least two isolated polypeptides or immunogenic fragments thereof, and optionally a ph...
|
|
WO/2016/147205A1 |
The present invention relates to novel substituted 3-spirophosphoryl, pyrazole-2-oxindoles of Formula (I) and its pharmaceutically acceptable salts, esters, ethers, isomers, stereoisomers, positional isomers and pplymorphs. The present i...
|
|
WO/2016/142922A1 |
The invention relates to compounds of formula (I), to the pharmaceutical compositions comprising same, and to the use thereof in the treatment of bacterial, fungal, viral and parasitic infections or in the treatment of cancer in humans o...
|
|
WO/2015/146870A9 |
Provided are a pyrimidine compound represented by formula (1) having excellent harmful pest-exterminating potency, a harmful pest-exterminating agent comprising the compound and an inert carrier, and a method for exterminating harmful pe...
|
|
WO/2016/142394A1 |
The invention relates to novel pyrazolyl-derivatives of general formula (I). The invention also relates to methods for producing the compounds of formula (I). The compounds according to the invention are particularly suitable for control...
|
|
WO/2016/143650A1 |
Provided is a compound that exhibits an excellent controlling effect against harmful arthropods. A 3-aminooxalylaminobenzamide compound represented by formula (1) has an excellent controlling effect against harmful arthropods.
|
|
WO/2016/143652A1 |
Provided is a compound that exhibits an excellent controlling effect against harmful arthropods. A 3-aminooxalylaminobenzamide compound represented by formula (1) has an excellent controlling effect against harmful arthropods. [In the fo...
|
|
WO/2016/138339A1 |
This invention relates to long-acting injectable formulations for combating parasites in animals, comprising at least one isoxazoline active agent, a poloxamer, and a co-solvent. This invention also provides for improved methods for erad...
|
|
WO/2016/131100A1 |
The present invention relates to methods of treating an infection in a subject in need thereof. In particular, the present invention relates to treating an infection by administering a therapeutically effective amount of a BCL2 family in...
|
|
WO/2016/134353A1 |
The present invention relates to the field of anti-malarials. In particular, the disclosure relates to methods for treating malaria in a subject by administering to said subject a potassium channel inhibitor. The disclosed potassium chan...
|
|
WO/2016/132134A1 |
The present invention relates to a novel class of compounds of general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, X and Y are as defined herein, to their use in human and veterinary medicine, and in the treatment of animal trypanoso...
|
|
WO/2016/127350A1 |
Disclosed are a preparation method for praziquantel and intermediates thereof. The method comprises: a target product praziquantel is obtained by using β-phenylethylamine as an initial raw material through the condensation reaction with...
|
|
WO/2016/129684A1 |
Provided is a novel noxious organism control agent, particularly an insecticide or a miticide. A condensed heterocyclic compound represented by formula (1) [wherein D substituted by -S(O)nR1 represents a ring represented by D1, D2 or D3;...
|
|
WO/2016/123973A1 |
A method for preparing an itraconazole preparation comprises dissolving a mixture of itraconazole and L-ascorbic acid with a mixed solvent of dichloromethane and methanol, adding hydroxypropyl methylcellulose and pluronic F-127 and then ...
|
|
WO/2016/121969A1 |
The present invention provides: a bipyridine compound that exhibits an excellent control effect against noxious arthropods and is represented by formula (I) [In the formula, R1 represents a C2-C10 haloalkyl group etc., R2 represents a C1...
|
|
WO/2016/123575A1 |
This disclosure is directed to compositions related to Plasmodium 6-domain polypeptides and related method of using the disclosed compositions to modulate binding and signaling of Eph receptors.
|
|
WO/2016/123152A1 |
The present disclosure is directed to compositions and methods for inhibiting either Toxoplasma gondii (T. gondii) calcium dependent protein kinases (TgCDPKs) or Cryptosporidium parvum (C. parvum) and Cryptosporidium hominus (C. hominus)...
|
|
WO/2016/121970A1 |
The present invention provides: a bipyridine compound that exhibits an excellent control effect against noxious arthropods and is represented by formula (1) [In the formula, L represents a single bond etc., R1 represents a C1-C10 chain h...
|
|
WO/2016/116550A1 |
An immunotoxin for use in the treatment of leishmaniasis wherein the immunotoxin comprises a portion which is specifically binding to the cellular surface receptor CD64 as a component A and a cell killing portion as a component B, wherei...
|
|
WO/2016/116752A1 |
The 3,3,3-trifluoro-N-((1,4-trans)-4-((4-methoxy-3-(2-methoxyphe
nyl)-1H- pyrazolo[3,4-d]pyrimidin-6-yl)amino)cyclohexyl)propane-1-sul
fonamide, having the Formula (I): (I) or a salt thereof, compositions comprising the compound, its use...
|
|
WO/2016/118638A1 |
The present invention relates to novel anthelmintic compounds of formula (IA) below: wherein, Y is selected from the group consisting of -H, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocyclyl, alkyl, haloalkyl, and alkoxyalkyl; and...
|
